Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in paragon-hf
Karola S. Jering,Finnian R. Mc Causland,Faiez Zannad,Brian Claggett,Marty P. Lefkowitz,Burkert Pieske,Jean L. Rouleau,Victor Shi,Turia Ben-Gal,Carolyn S.P. Lam,Sanjiv J. Shah,John J.V. McMurray,Scott D. Solomon,Marc A. Pfeffer +13 more
About:
This article is published in Journal of the American College of Cardiology.The article was published on 2020-03-24 and is currently open access. It has received 8 citations till now. The article focuses on the topics: Mineralocorticoid receptor.read more
Citations
More filters
Journal ArticleDOI
Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management
Andreas B. Gevaert,Rachna Kataria,Faiez Zannad,Andrew J. Sauer,Kevin Damman,Kavita Sharma,Sanjiv J. Shah,Harriette G.C. Van Spall +7 more
TL;DR: A narrative review summarises the pathophysiology, diagnosis, classification and management of patients with HFpEF and suggests classification based on phenotypes may facilitate a more targeted approach to treatment than LVEF categorisation.
Journal ArticleDOI
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Wilfried Mullens,Pieter Martens,Jeffrey M. Testani,W.H. Wilson Tang,Hadi Skouri,Frederik H. Verbrugge,Marat Fudim,Massimo Iacoviello,Jennifer Franke,Andreas J. Flammer,Alberto Palazzuoli,P. M. Barragán,Thomas Thum,Marta Cobo Marcos,Òscar Miró,Patrick Rossignol,Marco Metra,Johan Lassus,Francesco Orso,Ewa A. Jankowska,Ovidiu Chioncel,Davor Miličić,Loreena Hill,Petar M. Seferović,Giuseppe M.C. Rosano,Andrew J.S. Coats,Kevin Damman +26 more
TL;DR: Advice is provided of the effect HF drugs on renal function as the emerge of several new classes and the recommendation by the 2021 ESC guidelines of early initiation and titration of quadruple disease‐modifying therapies in HFrEF increases the likelihood of treatment‐induced changes in renal function.
Journal ArticleDOI
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Mona Fiuzat,Carine E. Hamo,Javed Butler,William T. Abraham,Ersilia M. DeFilippis,Gregg C. Fonarow,JoAnn Lindenfeld,Robert J. Mentz,Mitchell A. Psotka,Scott D. Solomon,John R. Teerlink,Muthiah Vaduganathan,Orly Vardeny,John J.V. McMurray,Christopher M. O'Connor +14 more
TL;DR: The Heart Failure Collaboratory as mentioned in this paper discussed standardization of background drug therapy in clinical trials in patients with heart failure and provided potential conceptual approaches, with a focus on therapies indicated for heart failure with reduced ejection fraction.
Journal ArticleDOI
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure
TL;DR: It is proposed that foundational HF treatments should be applied to patients across broad range of EF, with attenuation of the effect on HF hospitalization in patients with EF >55-60%.
Journal ArticleDOI
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
Miyesaier Abudureyimu,Xuanming Luo,Xiangrui Wang,James R. Sowers,Wenshuo Wang,Junbo Ge,Jun Ren,Yingmei Zhang +7 more
TL;DR: Findings from multiple preclinical and clinical studies as well as recent clinical trials are summarized, mainly focusing on the pathophysiology, potential mechanisms, and therapies of HFpEF in T2D.
References
More filters